Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study-Reference-Cited by-同舟云学术

Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study

Published:2023-07-20 Issue: Volume: Page:1-11
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Ticau Simina¹^ORCID,Aldinc Emre¹^ORCID,Polydefkis Michael²^ORCID,Adams David³^ORCID,Coelho Teresa⁴,Ueda Mitsuharu⁵^ORCID,Hale Cecilia¹,Vest John¹,Nioi Paul¹^ORCID,

Affiliation:

1. Alnylam Pharmaceuticals, Cambridge, MA, USA

2. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

3. Neurology Department, AP-HP, CHU Bicêtre, Université Paris-Saclay, Paris-Saclay, France

4. Centro Hospitalar Universitário Santo António, European Reference Network – EUroNMD, Porto, Portugal

5. Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Publisher

Informa UK Limited

Subject

Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2023.2232520